Skip to main content
SpringerLink
Log in

Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases

  • Book
  • © 2020

Overview

Editors:
  1. Christopher L. Cioffi

    1. Departments of Basic and Clinical Sciences and Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Albany, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Presents the current state of ocular drug therapy
  • Reviews the unique challenges faced for ocular drug discovery and delivery
  • Highlights future therapeutic opportunities for age-related macular degeneration, diabetic retinopathy, and glaucoma
  • Written by well-known experts

Part of the book series: Topics in Medicinal Chemistry (TMC, volume 35)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (7 chapters)

  1. Front Matter

    Pages i-ix
    Download chapter PDF

  2. Introduction: Overview of the Human Eye, Mammalian Retina, and the Retinoid Visual Cycle

    • Christopher L. Cioffi
    Pages 1-42

  3. Ocular Pharmacokinetics and Drug Delivery Challenges

    • Michael W. Stewart
    Pages 43-81

  4. Models of Pathologies Associated with Age-Related Macular Degeneration and Their Utilities in Drug Discovery

    • Goldis Malek, Pei-Li Yao, Mayur Choudhary
    Pages 83-123

  5. Recent Developments in Agents for the Treatment of Age-Related Macular Degeneration and Stargardt Disease

    • Konstantin Petrukhin
    Pages 125-160

  6. Emerging Therapeutic Modalities for Diabetic Retinopathy

    • MD Imam Uddin, Ashwath Jayagopal
    Pages 161-187

  7. Recent Developments for the Treatment of Glaucoma

    • Christopher M. Adams, Julien P. N. Papillon
    Pages 189-256

  8. Emerging Gene Therapy Approaches Under Clinical Investigation for Retinal Degenerative Diseases

    • Benjamin Bakall, Kendra Klein, Katrina Mears
    Pages 257-272
Back to top

Keywords

About this book

This book reviews the current state of ocular drug therapy and future therapeutic opportunities for a wide variety of conditions, including Age-related Macular Degeneration, Diabetic Retinopathy and Macular Edema, Glaucoma, and Inherited Retinal Diseases.

Retinal diseases are major contributors to moderate or severe vision impairment in adults aged 50 years and older. The respective patient populations for many of these indications is expected to significantly increase as the world population continues to grow older. An improved understanding of the etiological underpinnings of ocular degenerative diseases over the past decade has significantly bolstered ophthalmic drug discovery.

In this volume, contributions from leading experts explore the unique challenges faced for ocular drug discovery and delivery providing the reader with detailed information on ocular pharmacokinetics, in vitro, ex vivo and in vivo models for retinal disease pathology and emerginggene therapy treatments. The book is intended for all researchers and clinicians who wish to increase their knowledge on the latest findings in ocular drug therapy.

Editors and Affiliations

  • Departments of Basic and Clinical Sciences and Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Albany, USA

    Christopher L. Cioffi

About the editor

Christopher L. Cioffi is an Assistant Professor of Medicinal Chemistry in the Department of Basic and Clinical Sciences and the Department of Pharmaceutical Sciences at Albany College of Pharmacy and Health Sciences. Christopher received his doctorate in Organic Chemistry from Rensselaer Polytechnic Institute in 2000. He subsequently conducted a 16-year career as a medicinal chemist at Albany Molecular Research, Inc. where he led numerous medicinal chemistry teams and made significant drug design contributions to programs that advanced drug candidates into pre-clinical development and clinical trials. His work has spanned several therapeutic areas that include cardiovascular, gastrointestinal, CNS, and ophthalmic indications. Notably, Christopher has contributed to the discovery of Eli Lilly’s cholesteryl ester transfer protein inhibitor evacetrapib, which progressed to Phase III clinical trials for dyslipidemia. Additionally, he has co-discovered the 5-HT3 partial agonist SMP-100 (SciMount Therapeutics) to be studied for efficacy against IBS-D and the retinol binding protein 4 antagonist tinlarebant (Belite Bio) for the treatment of Stargardt disease. Tinlarebant has completed Phase I clinical trials and Phase II trials with Stargardt disease patients are expected to commence in 2020. SMP-100 is currently undergoing Phase I clinical trials. Christopher joined Albany College of Pharmacy and Health Sciences in 2016 and is engaged drug discovery projects focused in the areas of atrophic age-related macular degeneration and chronic pain.

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation